Compare AU

Compare CURE vs. EBND

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and EBND. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

CURE

EBND

Popularity

Low

Low

Pearlers invested

83

11

Median incremental investment

$619.50

$1,000.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$1,747.46

Average age group

> 35

> 35


Key Summary

CURE

EBND

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

EBND.AX was created on 2020-02-11 by VanEck. The fund's investment portfolio concentrates primarily on broad credit fixed income. EBND.AX aims to provide investors with a globally diversified portfolio of bonds and currencies in emerging markets. The fund aims to provide total investment returns, measured over the medium to long term in excess of the Benchmark

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

VanEck Emerging Inc Opportunities Active ETF (Managed Fund) (100 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Management fee

0.45 %

0.95 %


Key Summary

CURE

EBND

Issuer

Global X

VanEck

Tracking index

S&P Biotechnology Select Industry

Asset class

ETF

ETF

Management fee

0.45 %

0.95 %

Price

$51.33

$10.34

Size

$36.301 million

$170.273 million

10Y return

N/A

N/A

Annual distribution/ dividend yield (5Y)

4.24 %

5.17 %

Market

ASX

ASX

First listed date

12/11/2018

13/02/2020

Purchase fee

$6.50

$6.50


Community Stats

CURE

EBND

Popularity

Low

Low

Pearlers invested

83

11

Median incremental investment

$619.50

$1,000.00

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$1,747.46

Average age group

> 35

> 35


Pros and Cons

CURE

EBND

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher price growth

  • Higher distribution yield

Cons

  • Lower price growth

  • Lower distribution yield

  • Lower exposure to US market

  • Higher management fee

CURE

EBND

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Lower distribution yield

Higher distribution yield

Home